Tecadenoson

DB04954InvestigationalSmall molecule

Tecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm. It is being developed by...

Mechanism: Tecadenoson selectively stimulates the A1 adenosine receptor. Stimulation of the A1 adenosine receptor slows the conduction of electrical impulses in the AV node of the heart, a region that controls the transmission of electrical impulses from the atria to the ventricles.
Curator reviewed
Primary indication: Investigated for use/treatment in arrhythmia and atrial fibrillation.Curator reviewed
Formula / weight: C₁₄H₁₉N₅O₅ · 337.3312 g/mol (avg)
Code names: CVT-510

Resolves to

Compound

UNIIGZ1X96601ZCAS204512-90-3ChEMBLCHEMBL392149ChEBI748802PubChem158795

Structure

InChIKeyOESBDSFYJMDRJY-BAYCTPFLSA-NSMILESOC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C(N[C@@H]3CCOC3)N=CN=C12

Targets

P30542ADORA1

What you can answer from here — as of October 01, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

11+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tecadenoson, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account